Search Results
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 studyPresentation Type: Presidential Symposium Presentation #:
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 23, 2025, 03:46 ET AI in Oncology For Analytical Solutions Market Size & Share to Surpass $8.86 Billion by 2035, Growing at a CAGR 21% | Vantage Market Research
of AI-powered diagnostics for imaging, risk prediction, and therapy personalization due to its prevalence and early detection initiatives.Lung Cancer: AI tools support early detection, tumor classification, and response monitoring, improving outcomes for a high-mortality indication.Prostate
More news about: Vantage Market Research
Sep 22, 2025, 22:56 ET Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation
evaluates ivonescimab in combination with chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC), has been selected for the Presidential Symposium. The study's principal investigator, Professor Lu Shun, Director of the Department
More news about: Akeso, Inc.
Sep 22, 2025, 22:16 ET Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
of China for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC). This acceptance for review is based on the positive results from the two pivotal Phase 2 cohorts of the KL400-I/II-01 study for both
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 13:14 ET Support Immune Health with 4 Everyday Habits
heart-healthy grapes to your daily diet can help support brain, colon and skin health. Grapes are also a good source of vitamin K, which may help support lung health. Avoid Others Who are Sick: Along with washing your hands frequently, steering clear of people who are ill may sound like a no-brainer,
More news about: Family Features Editorial Syndicate
Sep 22, 2025, 11:07 ET Feed Antioxidants Market Driven by Rising Demand for Animal Nutrition and Expanding at a Robust CAGR of 7.2% Between 2026 and 2033 - Market Research Intellect
Neoantigen Vaccine Market is categorized based on Application (Melanoma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Head and Neck Cancer, Glioblastoma, Triple-Negative Breast Cancer, Gastro-Esophageal Cancer, Ovarian Cancer, Colorectal
More news about: Market Research Intellect
Sep 22, 2025, 08:30 ET IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Sep 22, 2025, 08:07 ET Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling. About Lung Cancer Lung cancer is the
More news about: Quest Diagnostics
Sep 22, 2025, 08:05 ET Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Sep 22, 2025, 08:00 ET Thynk Health Appoints Matt Rockhold as Chief Commercial Officer to Accelerate AI-Driven Cancer Detection Across U.S. Health Systems
complex healthcare ecosystems. At Thynk Health, Rockhold is responsible for accelerating adoption of the company's category-defining platform for lung cancer screening and incidental findings management. The AI-powered solution transforms manual workflows into streamlined, automated, and compliant
More news about: Thynk Health
Sep 22, 2025, 07:00 ET Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
adolescent patients. About Bronchiectasis Bronchiectasis is a serious, chronic lung disease in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by frequent pulmonary exacerbations requiring antibiotic
More news about: Insmed Incorporated
Sep 22, 2025, 04:26 ET SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
false and misleading statements to the market. Summit misled investors about the results of its Pinnacle Study of poziotinib, a potential treatment for lung cancer patients. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market
More news about: The Schall Law Firm
Sep 22, 2025, 02:00 ET TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced a strategic collaboration with Mercedes-Benz Group AG to deploy a first-of-its-kind fleet of modern, purpose-built
More news about: TransMedics Group, Inc.
Sep 22, 2025, 02:00 ET TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced a strategic collaboration with Mercedes-Benz Group AG to deploy a first-of-its-kind fleet of modern, purpose-built
More news about: TransMedics Group, Inc.
Sep 21, 2025, 09:06 ET SVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,
More news about: THE ROSEN LAW FIRM, P. A.
Sep 20, 2025, 14:00 ET SPPI Deadline: SPPI Investors with Losses in Excess of $100K Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
made false or misleading statements to investors regarding its PINNACLE Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Spectrum class action,
More news about: THE ROSEN LAW FIRM, P. A.
Sep 19, 2025, 08:42 ET aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman
over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal.
More news about: Hagens Berman Sobol Shapiro LLP
Sep 19, 2025, 08:30 ET Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress
and peripheral sensory neurons. Mast cells are critical regulators of immune response and can be found in most vascularized tissues including skin, lung and the digestive tract. The receptor is activated by a broad spectrum of ligands that are prevalent during inflammation. Targeting MRGPRX2 may have
More news about: Evommune, Inc
Sep 19, 2025, 08:00 ET Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
https://www.antengene.com/newsinfo/442 For more information, please contact: Investor Contacts: Donald LungE-mail: [email protected] Mobile: +86 18420672158
More news about: Antengene Corporation Limited
Sep 19, 2025, 08:00 ET Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: [email protected] Mobile: +86 18420672158
More news about: Antengene Corporation Limited